EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSEEEG00000012769
Gene Symbol: CACNG7
4 Cross references
190 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSEEEG00000012767
Gene Symbol: CACNG8
4 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSEEEG00000007794
Gene Symbol: CACNA1A
2 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSEEEG00000015148
Gene Symbol: CACNA1B
2 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSEEEG00000011866
Gene Symbol: CACNA1E
2 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSEEEG00000002272
Gene Symbol: CACNA1G
4 Cross references
197 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSEEEG00000006016
Gene Symbol: CNR1
1 Cross references
153 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSEEEG00000010474
Gene Symbol: CNR2
4 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSEEEG00000001658
Gene Symbol: CA12
4 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSEEEG00000002021
Gene Symbol: LOC113577544
4 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSEEEG00000014732
Gene Symbol: CA6
4 Cross references
230 Possible Orthologues:

Carbonic Anhydrase Iv B

Ensembl ID : ENSEEEG00000003756
Gene Symbol: CA4B
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).